Anatomy and Cell Biology

Korean Association of Anatomists (대한해부학회)
권호 표지

Protective Effect of Fibroin BF-7 on Neuronal Cell Death in Alzheimer Model using Amyloid $\beta$ Peptide

아밀로이드 베타 단백질을 이용한 알츠하이머 모델에서 유도되는 신경세포 사멸에 대한 피브로인 BF-7의 뇌기능 보호 작용에 관한 연구

Lee, Do-Yeon;Yu, Ji-Young;Kim, Jang-Il;Kim, Do-Hee;Han, In-Sook;Lee, Won-Bok
이도연;윤지영;김장일;김도희;한인숙;이원복

  • Published : 20070300
⟨ Previous Next ⟩

Abstract

Factors such as senescence, stress and neurodegenerative diseases, including Alzheimer’s disease, contribute to the impairment of organs, especially the brain. They also negatively affect normal brain functions such as memory and cognition. In this study, the neuroprotective role of the natural product BF-7 was examined against Aβ- induced neurotoxicity in SK-N-SH human neuronal cells. BF-7 significantly attenuated Aβ-induced apoptosis as measured by intracellular calcium levels, accumulation of reactive oxygen species, mitochondrial dysfunction, and caspase activity. These results strongly indicate that BF-7 plays an effective and positive role in the improvement of brain functions, including learning and memory, in our model system for Alzheimer’s disease. Thus, BF-7 might be useful for developing strategies to protect the nervous system and improve brain function.

본 연구에서는 피브로인 BF-7이 아밀로이드 베타 단백질에 의한 신경독성에 대해 보호작용을 나타 낼 수 있는지를 알아보고자 하였다. 사람의 인지기능을 담당하는 뇌신경세포 SK-N-SH 세포주를 이용하여, 아밀 로이드 베타 단백질의 투여에 의한 신경세포사멸 유무와 세포사멸이 어떠한 양상인지 확인하고자 하였다. 본 연 구 결과, 아밀로이드 베타 단백질 처리에 의한 세포 내 칼슘 증가와 활성기 산소종의 증가 및 사립체 막전위차 의 손상이나 싸이토크롬씨(cytochrome c)의 세포질로의 방출과 같은 사립체의 기능 손상과 caspase 활성화가 유 도되었다. 그러나, BF-7을 전처리한 경우, caspase의 활성화가 감소되고, 세포내 칼슘의 농도가 감소하였으며, 활 성기 산소종의 증가가 저해되었다. 뿐만 아니라, 사립체 막전위차의 손상이나 싸이토크롬씨의 세포질 방출과 같 은 사립체 기능 손상이 효과적으로 억제되어 궁극적으로 신경보호효과를 나타내었다. 이러한 결과는 피브로인 BF-7이 아밀로이드 베타에 의해 유도되는 신경세포 손상에 대해 효과적인 치료 방법으로 이용될 수 있을 뿐 아니라 향후 알츠하이머병의 발병 기전 및 다양한 신경퇴행성질환에 대한 보호작용을 나타내는 치료제 개발에 중요한 정보와 자료로 제공될 수 있음을 의미한다.

Keywords

References

  1. Amenta F, Parnetti L, Gallai V, Wallin A: Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors: Ineffective treatments or inappropriate approaches? Mech Ageing Dev 122: 2025-2040, 2001 https://doi.org/10.1016/S0047-6374(01)00310-4
  2. Andersen JK: Oxidative stress in neurodegeneration: Cause or consequence? Nature Neurosci 1: 518-523, 2004
  3. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC: Inhibition of Bax channel-forming activity by Bcl-2. Science 18: 370-372, 1997
  4. Antonsson B, Martinou JC: The Bcl-2 protein family. Exp Cell Res 10: 50-57, 2000
  5. Campion D, Brice A, Dumanchin C, Puel M, Baulac M, De La Sayette V, Hannequin D, Duyckaerts C, Michon A, Martin C, Moreau V, Penet C, Martinez M, Clerget-Darpoux F, Agid Y, Frebourg T: A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. Neuroreport 8: 1582-1584, 1996
  6. Chae HS, Kang YK, Shin YK, Lee HJ, Yu JI, Lee KG, Yoo JH, Kim YS, Shon DS, Kim KY, Lee WB, Lee SH, Kim SS: The role of BF-7 on neuroprotection and enhancement of cognitive function. Korean J Physiol Pharmacol 8: 173- 179, 2004
  7. Chu CT, Levinthal DJ, kulich SM, Chalovich EM, CeFranco DB: Oxidative neuronal injury. Eur J Biochem 271: 2060-2066, 2004 https://doi.org/10.1111/j.1432-1033.2004.04132.x
  8. Cleeter MW, Cooper JM: Schapira AH: Nitric oxide enhances MPP (+) inhibition of complex I. FEBS Lett 24: 50-52, 2001
  9. Emerit J, Edeas M, Bricaire F: Neurodegenerative disease and oxidative stress. Biomedicine and Pharmacotherapy 58: 39-46, 2003
  10. Fayuk D, Yakel JL: Regulation of nicotinic acetylcholine receptor channel function by acetylcholinesterase inhibitors in rat hippocampal CA1 interneurons. Mol Pharmacol 66: 658- 666, 2004 https://doi.org/10.1124/mol.104.000042
  11. Forloni G, Tagliavini F, Bugiani O, Salmona M: Amyloid in Alzheimer's disease and prion-related encephalopathies: Studies with synthetic peptides. Prog Neurobiol 49: 287- 315, 1996 https://doi.org/10.1016/0301-0082(96)00013-5
  12. Geldmacher DS, Whitehouse PJ: Evaluation of dementia. N Engl J Med 335: 330-336, 1996 https://doi.org/10.1056/NEJM199608013350507
  13. Giacobini E: Cholinesterase inhibitors stabilize Alzheimer's disease. Ann NY Acad Sci 920: 321-327, 2000 https://doi.org/10.1111/j.1749-6632.2000.tb06942.x
  14. Gonzalez-Polo RA, Soler G, Alonso JC, Rodriguez-Martin A, Fuentes JM: MPP (+) causes inhibition of cellular energy supply in cerebellar granule cells. Neurotoxicology 24: 219-225, 2003 https://doi.org/10.1016/S0161-813X(02)00164-X
  15. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF, Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T, Hofman A: Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1: 78-84, 1999
  16. Liu Q, Zhao B: Nicotine attenuates beta-amyloid peptide-induced neurotoxicity, free radical and calcium accumulation in hippocampal neuronal cultures. Br J Pharmacol 141: 746- 754, 2004 https://doi.org/10.1038/sj.bjp.0705653
  17. Mattson MP, Daun W, Pedersen WA, Culmsee C: Neurodegenerative disorders and ischemic brain disease. Apoptosis 6: 69-81, 2001 https://doi.org/10.1023/A:1009676112184
  18. Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med 341: 1670-1679, 1999 https://doi.org/10.1056/NEJM199911253412207
  19. Mizuno Y, Ikebe S, Hattori N, Kondo T, Tanaka M, Ozawa T: Mitochondrial energy crisis in Parkinson's disease. Adv Neurol 60: 282-287, 1993
  20. Selkoe DJ: Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271: 18295-18298, 1996 https://doi.org/10.1074/jbc.271.31.18295
  21. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760, 1995 https://doi.org/10.1038/375754a0
  22. Shimoke K, Chiba H: Nerve growth factor prevents 1-methyl-4- penyl-1, 2, 3, 6-tetrahydropyridine-induced cell death via the Akt athway by suppressing caspase-3-like activity using PC12 cells: relevance to therapeutical application for Parkinson's disease. J Neurosci Res 63: 402-409, 2001 https://doi.org/10.1002/1097-4547(20010301)63:5<402::AID-JNR1035>3.0.CO;2-F
  23. Soto C, Barnes MC, Alzarez J, Inestrosa NC: Structural determinants of the Alzheimer's amyloid $\beta$-peptide. J Neurochem 63: 1191-1198, 1994 https://doi.org/10.1046/j.1471-4159.1994.63041191.x